aldo-keto

Phenethyl trans-cinnamate is an aromatic ester found in various plants. It is an important intermediate in the synthesis of various drugs and spices, and is also used in the synthesis of various flavors, fragrances and cosmetics.

AKR1C3-IN-9, a selective Aldo-keto Reductase 1C3 (AKR1C3) inhibitor (IC50 = 8.92 nM), can significantly reverse Doxorubicin (DOX) resistance in a resistant breast cancer cell line.

S19-1035 is a potent and specific inhibitor of aldo-keto reductase 1C3 (AKR1C3), displaying an inhibitory concentration (IC50) of 3.04 nM. It is primarily utilized in tumor research.

OBI-3424, a highly selective prodrug, is converted by aldo-keto reductase family 1 member C3 (AKR1C3) to a potent DNA-alkylating agent.

SN34037 is a specific Aldo-keto reductase 1C3 (AKR1C3, EC 1.1.1.188) inhibitor.

MDK-0738 is a potent and selective aldo-keto reductase 1C3 inhibitor.

AKR1C3-IN-4, a potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3) with an IC50 of 0.56 μM, shows potential for castrate-resistant prostate cancer (CRPC) research.

AKR1B10-IN-1, a powerful AKR1B10 (Aldo-Keto Reductase 1B10) inhibitor, demonstrates an IC50 value of 3.5 nM. This compound effectively curtails the proliferation, metastasis, and Cisplatin (CDDP) resistance of lung cancer cells.

Obafistat is a potent inhibitor of aldo-keto reductase AKR1C3 with an IC50 of 1.2 nM for human AKR1C3.

S07-2009 is a potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3) with an IC50 of 0.20 μM [1].

S07-2001 enhances Doxorubicin against cancer cells activity, which can be used as a chemotherapeutic potentiator for cancer drug resistance. S07-2001 is a potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3) with an IC 50 value of 2.08 μM [1].

S07-2005 racemic is a chemically potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3), with an IC50 value of 0.13 μM and 0.75 μM for AKR1C3 and AKR1C4, respectively. Due to its inhibitory properties, it exhibits potential as a chemotherapeutic potentiator, specifically in the context of overcoming drug resistance in cancer [1].

S07-2008 is a selective inhibitor of aldo-keto reductase family 1 member C3 (AKR1C3) (IC50: 0.16 μM) and has anticancer effects.

Obafistat Na is an aldo-keto reductase AKR1C3 inhibitor.

S07-1066, an aldo-keto reductase 1C3 (AKR1C3) inhibitor, enhances doxorubicin (DOX) cytotoxicity by selectively inhibiting AKR1C3-mediated reduction of DOX and reversing DOX resistance in cells with elevated AKR1C3 expression [1].

AKR1C3-IN-12 (compound 2j), an inhibitor of aldo-keto reductase 1C3 (AKR1C3), exhibits potent activity with an IC50 of 27 nM. It has been shown to enhance the effectiveness of Gemcitabine and Cisplatin in treating bladder cancer [1].